Annovis Bio, Inc.
ANVS · XNYSCIK 1477845fmd_0VFR9ZJ0QDYERQHH9375A49JC9Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2019 to Sep 30, 2026, 31 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Research and development | 1 | 3 | 8 | 17 | 39 | 20 | 25 |
| Total operating expenses | 2 | 7 | 15 | 26 | 45 | 27 | 30 |
| Operating income | (2) | (7) | (15) | (26) | (45) | (27) | (30) |
| Interest and investment income | – | – | – | – | 1 | 0 | 1 |
| Other non-operating income (expense) | 1 | 1 | 0 | 0 | (11) | 2 | 1 |
| Income before taxes | (1) | (5) | (14) | (25) | (56) | – | – |
| Income tax expense | 0 | – | – | – | – | – | 0 |
| Net income from continuing operations | (1) | – | – | – | – | – | – |
| Net income | (1) | (5) | (14) | (25) | (56) | (25) | (29) |
| Net income to common shareholders | – | – | – | – | (56) | (28) | (29) |